Breast Cancer

EA1181 / CompassHER2 pCR

Preoperative THP & Postoperative HP in Patients who Achieve a Pathologic Complete Response

Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2 positive breast cancer

Physician and Research Staff Educational Material

This material is intended for promotional use among health care professionals and is NOT intended for use as patient educational material.

Patient Educational Material

Participating sites should note that the Central Institutional Review Board (CIRB) has approved this material.

Patient Video

Study Chair Nadine Tung, MD of Beth Israel Deaconess Medical Center discusses EA1181/CompassHER2 pCR, a clinical trial that aims to optimize the amount of chemotherapy that patients with HER2-positive breast cancer receive.

ECOG-ACRIN Cancer Research Group